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tients) were hypoglycemia (17.6%, predictors: young age, 
diagnosis of Laron syndrome, but not rhIGF-1 dose), lipohy-
pertrophy (10.6%), tonsillar hypertrophy (7.4%), injection 
site reactions (6.4%), and headache (5.9%). Sixty-one serious 
adverse events (37 related to rhIGF-1 therapy) were reported 
in 31 patients (16.5%).  Conclusion: Safety and effectiveness 
data on use of rhIGF-1 in a ‘real-world’ setting were similar to 
those from controlled randomized trials. Severe growth 
 phenotype and early start of rhIGF-1 improved height re-
sponse and predicted risk of hypoglycemia. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Growth disorders resulting from defects in the growth 
hormone–insulin-like growth factor-1 (GH–IGF-1) axis 
form a continuum, with severe GH deficiency (GHD) at 
one extreme and severe GH insensitivity at the other  [1, 
2] . In both conditions, severe IGF-1 deficiency, either sec-
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 Abstract 
 Background/Aims: We report data from the EU Increlex ® 
Growth Forum Database (IGFD) Registry, an ongoing, open-
label, observational study monitoring clinical practice use of 
recombinant human insulin-like growth factor-1 (rhIGF-1) 
therapy in children.  Methods: Safety and effectiveness data 
on rhIGF-1 treatment of 195 enrolled children with growth 
failure were collected from December 2008 to September 
2013.  Results: Mean ± SD (95% CI) height velocity during first 
year of rhIGF-1 treatment was 6.9 ± 2.2 cm/year (6.5; 7.2) 
(n  =  144); in prepubertal patients naïve to treatment, this 
was 7.3 ± 2.0 cm/year (6.8; 7.7) (n = 81). Female sex, younger 
age at start of rhIGF-1 therapy, and lower baseline height 
SDS predicted first-year change in height SDS. The most fre-
quent targeted treatment-emergent adverse events (% pa-
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ondary to GHD or primary in the case of GH insensitiv-
ity, causes significant growth retardation as the growth-
promoting effects of GH occur mostly via IGF-1 produc-
tion  [3] . Although various genetic defects  [4] have been 
identified with phenotypes varying from mild short stat-
ure without dysmorphic features to extreme growth fail-
ure associated with Laron syndrome  [5–7] , there are pa-
tients with severe primary IGF-1 deficiency [SPIGFD, de-
fined as height standard deviation score (SDS) less than 
or equal to –3, IGF-1 <2.5th percentile for age and sex (in 
the European Union) or IGF-1 SDS less than or equal to 
–3 (in the  United States), and normal or elevated GH se-
cretion  [8, 9] ] who do not yet have a genetic diagnosis.
 Recombinant human (rh)IGF-1 [mecasermin (rDNA 
origin) injection; Increlex ® ; Ipsen Pharma, Boulogne 
 Billancourt, France] is approved for the treatment of 
growth failure in children with SPIGFD. Acquired forms 
of IGF-1 deficiency, such as those due to malnutrition, 
hypothyroidism, or chronic treatment with pharmaco-
logical doses of anti-inflammatory steroids are excluded 
from this indication  [8, 9] .
 Clinical trials have demonstrated that children with 
SPIGFD respond to rhIGF-1 replacement therapy  [10, 
11] . However, the IGF-1-independent actions of GH on 
the growth plate cannot be normalized by rhIGF-1 treat-
ment. In addition, the activity of IGF-1 is affected by sev-
eral IGF-binding proteins (IGFBPs). The lack of GH- 
dependent IGFBP-3 and acid-labile subunit decreases the 
serum half-life of IGF-1, which may further contribute to 
incomplete catch-up growth in children with SPIGFD 
treated with rhIGF-1.
 GH and IGF-1 act in concert to promote linear growth, 
while their effects on glucose metabolism are opposed. In 
children with severe GHD as well as those with SPIGFD, 
the lack of GH glucoregulatory actions may cause sponta-
neous hypoglycemia  [8] . In SPIGFD, this tendency to de-
velop hypoglycemia may be further augmented during 
rhIGF-1 treatment and it is, therefore, the most common 
adverse event (AE)  [8, 9] . As expected, the risk of hypogly-
cemia appears to be related to the severity of the IGF-1 de-
ficiency and the lack of GH-dependent IGFBPs  [8, 9, 11] . 
On the other hand, lack of the insulin-like effects of IGF-1 
may contribute to the postprandial hyperglycemia ob-
served in SPIGFD, which is corrected by rhIGF-1 therapy 
 [10] . All rhIGF-1 injections should be given simultaneous-
ly with a meal, special attention should be paid to the risk 
of hypoglycemia after exercise, and glucose levels should 
be monitored in the case of hypoglycemic symptoms. Some 
of the other reported AEs associated with the mitogenic ef-
fects of rhIGF-1 are, to some extent, similar to those of 
rhGH, and include hypertrophy of lymphoid tissue caus-
ing tonsillar enlargement and compromised ventilation of 
the middle ear. Water retention with soft tissue swelling 
and, in rare cases, increased intracranial pressure have 
been reported  [10, 11] . Local injection site reactions in-
clude lipohypertrophy and redness of the skin  [10, 11] . 
Nonspecific symptoms, such as headache, have also been 
reported.
 The European Medicines Agency (EMA) approved 
rhIGF-1 (Increlex ® ) for the treatment of short stature in 
patients with SPIGFD with a requirement that clinical 
data should be captured in a registry. The EU Increlex ® 
Growth Forum Database (IGFD) Registry is an ongoing, 
open-label, observational study that started in December 
2008 and which has been initiated in 10 European coun-
tries to monitor the safety and effectiveness of rhIGF-1 
therapy in children in the clinical practice setting. The EU 
IGFD Registry also aims to monitor patients after the end 
of treatment and to the attainment of adult height. The 
experience of rhIGF-1 treatment in clinical trials with a 
carefully controlled patient population  [10–12] may dif-
fer from that in the clinical setting with a heterogeneous 
patient population; however, registries provide these 
 real-world data, which are currently lacking in this ther-
apy area. The objective of this article is to report safety 
and effectiveness data (up to 2 years) from children en-
rolled in the EU IGFD Registry up to September 30, 2013.
 Patients and Methods 
 Patients 
 Children were eligible for enrollment in the EU IGFD Registry 
if they were initiating or were currently receiving rhIGF-1 therapy 
prescribed by a participating qualified practitioner and gave in-
formed consent, if appropriate, in addition to mandatory consent 
from their parents or legally authorized representative. Children 
currently participating in either an rhIGF-1 clinical trial or in any 
clinical trial for growth retardation were excluded from the EU 
IGFD Registry. Participants or their legal representative could 
withdraw from the EU IGFD Registry at any time without affecting 
treatment or normal follow-up of the condition.
 Study Procedures 
 Anonymous data existing in the patients’ medical records as part 
of standard medical care were collected using an electronic Case 
Report Form. This included sex, birth data, parental heights, height 
and weight measurements prior to inclusion, previous therapy (in-
cluding details of growth-promoting therapy with rhGH, rhIGF-1, 
and/or steroids), data on work-up including medical history, GH 
secretory status, serum IGF-1 and IGFBP-3 concentrations, genetic 
testing, and bone age. The baseline clinical examination recorded 
pubertal stage, auxology (including height, weight, and sitting 
height), concomitant medication, and starting dose of rhIGF-1. 
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Baseline was defined as the visit closest to the start of  Increlex ® 
 treatment. If a patient had previously received growth-promoting 
treatment, including another preparation of rhIGF-1, baseline still 
referred to the visit closest to the start of Increlex ® therapy.
 The number and frequency of follow-up visits for each patient 
were determined by the investigator’s judgment on the basis of 
clinical need and rhIGF-1 label recommendations. The study de-
fined specific 6-monthly time points up to 60 months for the de-
scriptive analysis. Each visit was allocated to the time point closest 
to the visit. If several visits occurred within the same time window, 
only data collected at the visit nearest to the time point were used.
 Diagnosis was reported by the treating physician. Data collect-
ed during treatment included changes in rhIGF-1 dose and treat-
ment outcomes (e.g. height, weight, pubertal stage), concomitant 
medications, and serum IGF-1 concentrations.
 Safety data included serious adverse events (SAEs), targeted 
treatment-emergent adverse events (TEAEs, defined as targeted 
adverse events that have been historically associated with rhIGF-1 
treatment or that occurred either frequently whether or not they 
were considered to be drug-related by the reporting physician; 
treatment-emergent means occurring while treatment is ongoing) 
 [8] , treatment-related nonserious AEs, and clinically significant 
laboratory abnormalities, occurring from initiation of treatment 
(including retrospective events on treatment prior to the registra-
tion visit) up to completion in the EU IGFD Registry.
 The safety data were reviewed on at least an annual basis by 
an  independent data review board composed of pediatric endo-
crinologists. The EU IGFD Registry was conducted in compliance 
with independent ethics committees/institutional review boards 
(except in the UK, where ethical review is not required for this type 
of registry), informed consent regulations, the Declaration of 
 Helsinki, the International Conference on Harmonization, and the 
Good Epidemiological Practice Guidelines. In addition, the EU 
IGFD Registry adhered to all local regulatory requirements includ-
ing data protection requirements linked to the use of electronic 
data.
 Endpoints 
 The primary objective of the EU IGFD Registry was to collect 
long-term safety information on the use of rhIGF-1 therapy for the 
treatment of children with growth failure. The primary endpoints 
comprised: description and incidence of any SAE, including new 
onset and recurrence of neoplasia; incidence of all targeted TEAEs 
(both treatment related and nontreatment related), i.e. hypoglyce-
mia (suspected and documented: blood glucose level <50 mg/dl or 
2.78 mmol/l), lipohypertrophy at the injection site, tonsillar hyper-
trophy, otitis media, hearing loss, sleep apnea, intracranial hyper-
tension, papilledema, headache, acromegalic facial changes, ede-
ma, myalgia, gynecomastia, and cardiomegaly; incidence of any 
TEAEs considered by the reporting pediatric endocrinologist to 
be/not to be related to rhIGF-1 therapy, and description and inci-
dence of all clinically significant laboratory abnormalities.
 A secondary objective of the EU IGFD Registry was to obtain 
long-term effectiveness data for rhIGF-1 therapy in children with 
growth failure. Changes from baseline were calculated for height 
(cm and SDS), height velocity (cm/year), weight (kg and SDS), 
body mass index (BMI and SDS), bone age, and pubertal stage ac-
cording to the Tanner method.
 Local protocols and test recommendations were used rather 
than a central laboratory, and thus there was variation with respect 
to the assays employed. At each visit the following data were re-
corded: rhIGF-1 therapy compliance and exposure, serum IGF-1 
and IGFBP-3 concentrations, and genetic test results.
 Study Populations 
 This analysis reports results from five populations. Demo-
graphic data are presented for the enrolled population, which com-
prised all patients who were fully informed about the EU IGFD 
Registry, for whom written informed consent to participate was 
received, and who complied with the inclusion and exclusion cri-
teria. The effectiveness data are presented for the Registry popula-
tion, and comprised all enrolled patients who received at least one 
treatment and completed at least one follow-up visit. The Registry 
population also included two Registry subpopulations: prepubertal 
patients (Tanner stage 1 of genital development for boys and breast 
development for girls) at first rhIGF-1 intake who were also naïve 
to growth-promoting treatment (treatment-naïve/prepubertal 
population), and patients who had previously received growth-
promoting treatment or who were pubertal (Tanner stage 2 or 
above of genital or breast development for boys or girls, respec-
tively; previously treated/pubertal population). Safety data are re-
ported for the safety population, comprising patients who received 
at least one dose of rhIGF-1 and who attended at least one follow-
up visit or for whom there were poststudy treatment safety data. 
Safety data were also assessed in the treatment-naïve/prepubertal 
versus the previously treated/pubertal subpopulations within the 
safety population.
 Entering puberty during the first year of rhIGF-1 treatment 
could potentially affect the first-year change in height SDS and, 
therefore, a subpopulation of treatment-naïve/prepubertal chil-
dren that continued to be prepubertal at the first-year visit was also 
assessed.
 Data Analysis 
 For France and southern European countries, height and 
weight SDS were calculated using Sempé reference means and SD 
values  [13] , with reference values dependent on sex and age. As 
discrete values for age are contained within the Sempé curve, mean 
and SD for ages between two reference ages were imputed using 
linear interpolation. The SDS was calculated as:
( )interpolated
interpolated
value mean
SDS .
SD
-
=
 For France and southern European countries, BMI SDS was calcu-
lated using the French National Plan for Nutrition and Health 
(PNNS) reference means and SD values. 
 For the UK, Belgium, Germany, Sweden, and Poland, height, 
weight, and BMI SDS were calculated using UK reference values. 
The reference values, which are dependent on age and sex, were 
selected at the closest age below that of the patient. The SDS in each 
case was calculated as:
( )( )Lvalue M 1
SDS ,
LS
/ -
=
 where L is the reference power, M is the mean, and S is the coef-
ficient of variation. 
 Annualized year 1 height velocities (cm/year) were computed 
using baseline and year 1 (days 275–457) height values.
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 Statistical Analyses 
 Results are presented as descriptive analyses: mean and SD or 
median and two-sided 95% CI of the median, maximum-mini-
mum range, or 25th and 75th percentiles. For categorical variables 
the 95% CIs are provided to show whether population CIs overlap 
and thereby lack significant difference.
 A linear regression analysis was performed to identify predic-
tive factors for first-year height velocity and first-year change in 
height SDS in treatment-naïve/prepubertal patients. Sex, paren-
tal height (cm), height (SDS) at baseline, BMI at baseline, IGF-1 
(ng/ml) status at baseline, treatment dose [μg/kg twice daily (BID)] 
at rhIGF-1 initiation, and age (years) at treatment initiation were 
entered into the model as covariates. For univariate and multivar-
iate regression analyses, two-sided 95% CIs and p values are re-
ported. The significance level for multivariate analyses was fixed 
at 5%.
 In patients followed for at least 1 year, annualized height veloc-
ity (cm/year) was compared between those with an average year 1 
dose  ≤ 100 µg/kg BID and those who received an average year 1 
dose >100 µg/kg BID using a t test.
 The proportion of children with at least one hypoglycemic 
event was explored using a logistic regression model. In the case of 
multiple events, the first event was considered. Covariates includ-
ed age (years), sex, pubertal stage (prepubertal stage vs. pubertal 
stage) at baseline, dose (µg/kg BID) at the time of hypoglycemia 
[average dose (µg/kg BID) during first year of treatment for those 
without hypoglycemia], history of hypoglycemia, previous rhGH 
therapy, and Laron syndrome.
 Results 
 Patient Characteristics 
 From the 10 European participating countries a total 
of 195 patients (Austria 6, Belgium 1, France 35, Germany 
73, Italy 23, Poland 9, United Kingdom 22, Spain 20, 
 Sweden 6, The Netherlands 0) were enrolled in the EU 
IGFD Registry as of September 30, 2013, representing ap-
proximately 60% of the estimated population receiving 
rhIGF-1 treatment for short stature in elective countries 
(based on the number of patients treated with rhIGF-1 ac-
cording to the label  [14] ). At 12, 24, 36, 48, and 60 months, 
the number of patients who had attended visits were 151, 
104, 66, 25, and 5, respectively. This corresponds to a 
mean ± SD treatment duration of 832 ± 491 days (median 
798 days), which is equivalent to a total of 433 patient-
years on treatment (n = 190, data missing for 5 patients). 
In the treatment-naïve/prepubertal and the previously 
treated/pubertal groups, treatment durations were 835 ± 
457 days or 249 patient-years (n = 109; data missing from 
1 patient) and 827 ± 538 days or 178 patient-years (n = 79; 
data missing from 3 patients), respectively.
 Baseline characteristics for enrolled patients, treat-
ment-naïve/prepubertal patients (n = 110), and previous-
ly treated/pubertal patients (n = 82) are shown in  table 1 . 
Baseline characteristics between the treatment-naïve/
prepubertal and previously treated/pubertal populations 
were not significantly different except for mean age at 
first rhIGF-1 intake, which was 3.5 years earlier in the 
treatment-naïve/prepubertal group, and mean height 
and mean IGF-1 concentration, which were both lower in 
the treatment-naïve/prepubertal patients ( table  1 ). Of 
those diagnosed with SPIGFD, 7 treatment-naïve/prepu-
bertal patients and 9 previously treated/pubertal patients 
had a pretreatment height SDS greater than –3 according 
to the investigator. Calculated baseline height SDS great-
er than –3 were found in 48 treatment-naïve/prepubertal 
patients and in 23 previously treated/pubertal patients. In 
addition, 1 patient with data not available regarding pu-
bertal status and previous treatment was diagnosed with 
SPIGFD with a height SDS greater than –3.
 Of the total number of patients enrolled in the EU 
IGFD Registry, 165 (84.6%) had SPIGFD as their primary 
diagnosis according to the reporting physician. Of these 
patients, 28 were reported to have Laron syndrome (GH 
receptor deletion or mutation genetically confirmed in 26 
patients). Diagnoses other than SPIGFD were reported in 
24 of these patients, including small for gestational age 
(n = 4), Noonan syndrome (n = 3), bone dysplasia (n = 3), 
and diabetes mellitus (n = 2). The primary diagnosis in 
the remaining 30 patients who were not diagnosed with 
SPIGFD included: primary IGF-1 deficiency (n  = 17, 
56.7%), GH gene deletion with anti-GH antibodies (n = 2, 
6.7%), small for gestational age (n = 5, 16.7%), and bone 
dysplasia, diabetes mellitus, and Russell-Silver syndrome 
(n = 1, 3.3%, for each). Other primary diagnoses account-
ed for 10 patients (33.3%). The investigator was able to 
record more than one primary diagnosis for each patient.
 Previous growth-promoting therapy had been given to 
65 patients (33.3%): 52 of these (80.0%) had previously 
received rhGH treatment and 21 (32.3%) had received 
rhIGF-1. Both rhGH and rhIGF-1 had been given to 9 
patients (13.8%), either simultaneously or over different 
periods of time, and 5 patients (7.7%) had received steroid 
treatment (androgen in n = 1 and systemic glucocorti-
coids in n = 4) prior to inclusion in the EU IGFD Registry. 
Of those on previous rhGH therapy (n = 47), the median 
(95% CI) maximum rhGH dose was 0.05 mg/kg/day 
(0.04; 0.06) and the median duration of treatment was 2.2 
years (range: 0.2–12). Thus, in the majority of these pa-
tients, including 10 patients who were born small for ges-
tational age, a dose higher than that currently recom-
mended by the EMA (0.025–0.035 mg/kg/day for GHD 
and a maximum dose of 0.067 mg/kg/day for small for 
gestational age) had been used (with poor response).
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 rhIGF-1 Dosing 
 The recommended starting dose of rhIGF-1 is 40 
μg/ kg BID by subcutaneous injection  [8] . If no significant 
treatment-related AEs occur for at least 1 week, the dose 
may be raised in increments of 40 μg/kg to the maximum 
dose of 120 μg/kg BID. Within the Registry population, 
the median (95% CI) rhIGF-1 starting dose was 40.0 
μg/ kg BID (40.0; 40.0) (n = 186). Although dose escala-
tion was slower than recommended, a median dose of 
116.0 µg/kg BID (100.0; 120.0) was achieved at 12 months 
(n = 169). The recommended maximum dose was reached 
in most patients by 18 months (median 120.0 µg/kg BID, 
 Table 1.  Baseline characteristics of all enrolled patients and subgroups of the Registry population: treatment-naïve/prepubertal patients 
and previously treated/pubertal patients
Characteristic All enrolled patients (n = 195) Treatment-naïve/prepubertal 
patients (n = 110)
 Previously treated/pubertal 
patients (n = 82)
na mean ± SD
[95% CI]
median (25th, 
75th percentile)
na mean ± SD
[95% CI]
median (25th, 
75th percentile)
na mean ± SD
[95% CI]
median (25th, 
75th percentile)
Female, n 195 67 (34.4%)
[28.1; 41.3]
N/A 110 44 (40.0%)
[31.3; 49.3]
82 23 (28.0%)
[19.5; 38.6]
N/A
Age at first
injection, years
195 10.1±4.0
[9.5; 10.7]
10.6
(6.8, 13.2)
110 8.5±3.5
[7.8; 9.2]
8.3
(5.8, 11.2)
82 12.0±3.6
[11.2; 12.8]
12.4
(10.2, 14.5)
Height, cm 183 116.5±20.0
[113.6; 119.4]
118.5
(100.6, 133.5)
105 110.2±19.3
[106.5; 113.9]
110.1
(96.0, 125.5)
75 124.2±17.8
[120.1; 128.2]
126.6
(112.0, 137.1)
Height SDS 183 −3.5±1.3
[−3.7; −3.3]
 −3.2
(−4.4, −2.6)
105 −3.4±1.3
[−3.6; −3.1]
−3.0
(−3.9, −2.5)
75 −3.8±1.3
[−4.1; −3.4]
−3.3
(−4.6, −2.7)
Weight SDS 182 −3.1±1.4
[−3.3; −2.9]
−3.0
(−3.8, −2.1)
104 −3.1±1.2
[−3.4; −2.9]
−3.1
(−3.7, −2.4)
75 −3.2±1.6
[−3.5; −2.8]
−2.9
(−4.1, −2.1)
BMI SDS 167 −0.7±1.5
[−1.0; −0.5]
−0.8
(−1.6, 0.0)
95 −0.8±1.3
[−1.1; −0.5]
−0.8
(−1.7, −0.1)
69 −0.7±1.7
[−1.1; −0.2]
−0.7
(−1.5, 0.0)
Bone age, years 38 8.5±3.5
[7.4; 9.6]
8.5
(5.5, 11.5)
22 7.4±3.0
[6.1; 8.7]
8.0
(5.0, 10.0)
15 9.7±3.7
[7.7; 11.8]
11.5
(6.8, 12.4)
Mother’s height, cmb 178 157.2±8.2
[156.0; 158.4]
158.0
(151.9, 163.0)
101 157.7±7.3
[156.3; 159.2]
158.0
(153.6, 162.0)
74 157.0±9.2
[154.7; 159.0]
157.5
(151.0, 164.0)
Father’s height, cmb 176 172.1±7.9
[170.9; 173.2]
172.0
(167.9, 178.0)
100 172.6±8.1
[171.0; 174.2]
173.0
(168.0, 178.0)
73 171.3±7.8
[169.5; 173.1]
172
(166.0, 177.0)
IGF-1, ng/mlc 167 120.7±121.6
[102.1; 139.3]
85.0
(44.0, 142.0)
90 91.8±71.0
[76.9; 106.6]
73.5
(38.9, 123.0)
74 157.3±157.7
[120.7; 193.8]
101.9
(54.0, 204.0)
GH test: stimulated, 
ng/ml
133 27.8±38.7
[21.1; 34.4]
16.8
(11.3, 29.0)
78 24.4±25.0
[18.7; 30.0]
15.6
(11.0, 26.1)
52 32.9±53.6
[18.0; 47.8]
18.1
(11.4, 39.0)
Height velocity,
cm/year
109 4.8±1.7
[4.5; 5.1]
4.7
(3.9, 5.6)
57 5.0±1.9
[4.5; 5.5]
5.1
(4.0, 6.2)
51 4.6±1.5
[4.2; 5.0]
4.4
(3.8, 5.4)
Primary diagnosis:
SPIGFDd, n
195 165 (84.6%)
[78.9; 89.0]
N/A 110 99 (90.0%)
[83.0; 94.3]
N/A 82 63 (76.8%)
[66.6; 84.6]
N/A
History of 
hypoglycemia, n
195 11 (5.6%) N/A 110 4 (3.6%) N/A 85 7 (8.2%) N/A
Prior growth-
promoting therapy, n
195 65 (33.3%)e
[27.1; 40.2]
N/A N/A N/A N/A N/A
 a Number of patients for whom data are available; pubertal status/previously treatment status was unknown for 3 patients. b Height SDS of 0 corresponds 
to 174.5 cm in males and 163.2 cm in females aged 18 years in the Sempé reference; height SDS of 0 corresponds to 177.1 cm in males and 163.6 cm in females aged 
18 years in the UK 1990 reference. c Wash-out period prior to rhIGF-1 therapy start not required in patients with prior growth-promoting treatment. d Including 
Laron syndrome. e rhGH in 52 (80.0%) and rhIGF-1 in 21 (32.3%). N/A = Not applicable.
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95% CI: 116.0; 120.0). Nevertheless, it is evident from 
 figure 1 that some patients did not reach the maximum 
dose of 120 µg/kg BID. Dosing was similar in the treat-
ment-naïve/prepubertal population (median values at 
baseline, month 12, and month 18 were 40, 110, and 
120 µg/kg BID, respectively). In the previously treated/
pubertal population, the maximum recommended dose 
of 120 µg/kg BID was already achieved by month 12.
 Effect of rhIGF-1 Therapy on Height, Weight, and 
BMI 
 Mean ± SD (95% CI) annualized height velocity dur-
ing the first year of rhIGF-1 treatment in the Registry pa-
tients was 6.9 ± 2.2 cm/year (6.5; 7.2) (n = 144). First-year 
height velocity in the treatment-naïve/prepubertal pa-
tients [7.3 ± 2.0 cm/year (6.8; 7.7); n = 81] tended to be 
higher than in previously treated/pubertal patients [6.3 ± 
2.4 cm/year (5.6; 6.9); n = 60]. Three patients did not have 
complete information on puberty/previous treatment. 
Changes in height and height SDS are provided in  table 2 .
 In treatment-naïve/prepubertal patients who contin-
ued to be prepubertal at 1 year, the mean ± SD first year 
change in height SDS was 0.5 ± 0.4 (n = 67) as compared 
with 0.4 ± 0.4 (n = 81) in all the treatment-naïve/prepu-
bertal patients ( table 2 ).
 Interestingly, treatment-naïve/prepubertal patients 
with Laron syndrome who were younger [mean age ± SD 
(95% CI): 6.4 ± 3.3 years (4.3; 8.6); n = 12] and shorter 
[mean height SDS ± SD (95% CI): –5.9 ± 1.7 (–7.0; –4.9); 
n = 11] at first rhIGF-1 intake than the treatment-naïve/
prepubertal population [8.5 ± 3.5 years (7.8; 9.2), n = 110 
and –3.4 ± 1.3 (–3.6; –3.1), n = 105, respectively] had a 
mean ± SD (95% CI) first-year gain in height SDS of 
0.7 ± 0.5 (0.3; 1.1) (n = 8) compared with 0.4 ± 0.4 (0.3; 
0.5) ( table 2 ) in the treatment-naïve/prepubertal patients.
 Height velocity at year 1 in treatment-naïve/prepu-
bertal patients with a mean rhIGF-1 dose  ≤ 100 µg/kg 
BID and >100 µg/kg BID was 7.2 and 7.4 cm/year, re-
spectively. In previously treated/pubertal patients with 
a mean rhIGF-1 dose  ≤ 100 µg/kg BID or >100 µg/kg 
BID, the first-year height velocity was 6.0 and 6.5 
cm/  year, respectively. These differences were not signif-
icantly different in either group. Predictors of a higher 
first-year change in height SDS in the treatment-naïve/
prepubertal population (multivariate analysis) includ-
ed: younger age at rhIGF-1 initiation [estimate; 95% CI 
by 1 unit increment: –0.04 (–0.06; –0.02); p < 0.001], fe-
male sex [0.18 (0.02; 0.33); p = 0.026], and lower height 
SDS at baseline [by 1 unit increment: –0.06 (–0.12; 
–0.00); p  = 0.041]. The only predictor (multivariate 
analysis) of a higher first-year height velocity in the 
treatment-naïve/prepubertal population was younger 
age at rhIGF-1 initiation [estimate; 95% CI by 1 unit in-
crement: –0.13 (–0.25; –0.01); p < 0.033]. No predictors 
for first-year change in height SDS were identified in the 
previously treated/pubertal population.
 The mean ± SD height response during the first 
2 years of treatment in the Registry population and in 
the treatment-naïve/prepubertal and previously treated/
pubertal subpopulations were 13.0 ± 3.7 cm (n = 98), 
13.6 ± 3.2 cm (n = 60), and 11.9 ± 4.2 cm (n = 38), respec-
tively ( table 2 ).
 The association between height velocity during the 
first and the second year of treatment demonstrated that 
treatment-naïve/prepubertal patients and previously 
treated/pubertal patients with a good first-year response 
had better linear growth during the second year than 
those with a poorer first-year response (R = 0.39, p = 
0.004 and R = 0.44, p = 0.006, respectively;  fig. 2 ).
 Weight and weight SDS increased more than height 
and tended to move BMI SDS slightly closer to zero in the 
Registry group as well as in both subpopulations ( table 2 ). 
A greater increase in height but smaller gain in BMI was 
seen in the treatment-naïve/prepubertal population com-
pared with the previously treated/pubertal group.
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 Fig. 1. rhIGF-1 therapy dose received during treatment period 
(155 patients with at least one follow-up visit). The size of the bub-
bles is proportional to the number of patients receiving the dose.
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 Table 2.  Height, weight, and BMI in the Registry population, treatment-naïve/prepubertal patients, and previously treated or pubertal 
patients
Heighta nb Mean ± SD, cm Mean SDS ± SD Change from baseline
na mean ± SD, cm mean SDS ± SD
Registry population
Baseline 176 116.6±20.0 −3.5±1.3 – – –
Year 1 151 123.7±20.0 −3.2±1.4 144 6.9±2.3 0.3±0.4
Year 2 104 128.3±20.5 −3.1±1.6 98 13.0±3.7 0.6±0.6
Treatment-naïve/prepubertal patients
Baseline 102 110.5±19.2 −3.4±1.3 – – –
Year 1 87 119.6±19.6 −2.9±1.3 81 7.3±2.0 0.4±0.4
Year 2 62 123.8±20.0 −2.9±1.5 60 13.6±3.2 0.7±0.6
Previously treated/pubertal patients
Baseline 71 124.2±17.9 −3.7±1.3 – – –
Year 1 63 128.9±18.9 −3.6±1.5 60 6.3±2.5 0.2±0.4
Year 2 42 134.8±19.7 −3.6±1.7 38 11.9±4.2 0.5±0.7
Weight na Mean ± SD, kg Mean SDS ± SD Change from baseline
na mean ± SD, kg mean SDS ± SD
Registry population
Baseline 174 23.0±9.6 −3.1±1.4 – – –
Year 1 151 27.2±10.9 −2.5±1.5 142 3.9±2.3 0.5±0.6
Year 2 104 30.9±12.7 −2.6±1.8 96 7.6±4.1 0.7±0.8
Treatment-naïve/prepubertal patients
Baseline 101 19.3±6.8 −3.1±1.2 – – –
Year 1 87 23.8±8.8 −2.5±1.5 80 3.4±1.7 0.5±0.6
Year 2 62 26.5±10.0 −2.3±1.9 59 6.9±3.7 0.8±0.8
Previously treated/pubertal patients
Baseline 70 27.5±10.5 −3.1±1.6 – – –
Year 1 63 31.7±11.7 −2.6±1.5 59 4.6±2.7 0.4±0.6
Year 2 42 37.5±13.5 −2.3±1.7 37 8.8±4.6 0.6±0.7
BMI na Mean ± SD, kg/m2 Mean SDS ± SD  Change from baseline
na mea n ± SD, kg/m2 mean SDS ± SD
Registry population
Baseline 161 16.3±3.1 −0.7±1.5 – – –
Year 1 151 17.1±3.3 −0.4±1.4 130 0.7±1.1 0.3±0.7
Year 2 104 18.1±4.2 −0.2±1.6 89 1.2±1.5 0.2±0.7
Treatment-naïve/prepubertal patients
Baseline 92 15.4±2.0 −0.8±1.3 – – –
Year 1 87 16.1±2.4 −0.6±1.4 72 0.5±1.0 0.2±0.7
Year 2 62 16.8±3.3 −0.5±1.6 54 1.0±1.4 0.2±0.7
Previously treated/pubertal patients
Baseline 66 17.3±3.9 −0.6±1.72 – – –
Year 1 63 18.4±3.9 −0.1±1.44 55 1.0±1.1 0.4±0.6
Year 2 42 20.0±4.8 0.2±1.6 35 1.6±1.7 0.2±0.6
a Median (Q1; Q3) of the time between the baseline and the year 1 height measurements: registry population: 365 (342; 403) days; 
treatment-naïve/prepubertal population: 365 (351; 394) days. b Number of patients for whom data are available at each time point; pu-
bertal status/previously treatment status was unknown for 3 patients.
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 Safety Profile of rhIGF-1 Therapy 
 Safety follow-up data were available for 188 patients; 
52.7% of patients (n = 99) reported one or more TEAEs 
(349 events). Most TEAEs (56.2% of events) were 
 considered to be related to treatment. One or more tar-
geted TEAEs was reported in 39.4% of patients (n = 74), 
with 84.5% of events being considered to be related to 
treatment.
 Targeted TEAEs 
 The most frequent targeted TEAE was hypoglycemia 
[59 events in 33 patients (17.6%)], including 26 events 
verified by blood glucose measurements (<2.78 mmol/l). 
Eight of the hypoglycemic events in 5 patients were con-
sidered to be serious. Four of 33 patients reporting hypo-
glycemia had a history of hypoglycemia. Univariate linear 
regression analysis did not identify a higher rhIGF-1 dose 
to be associated with hypoglycemia [odds ratio (OR) = 
1.0; 95% CI: 1.0; 1.0]. In the Registry population, 18 of 73 
patients (24.7%; 95% CI: 16.2; 35.6) with a dose at year 1 
of  ≤ 100 µg/kg BID had at least one episode of hypoglyce-
mia compared with 14 of 96 patients with a dose at year 1 
of >100 µg/kg BID (14.6%, 95% CI: 8.9; 23.0). Univariate 
linear regression analysis demonstrated that hypoglyce-
mia was related to age at the start of treatment [OR = 0.9 
(95% CI: 0.8; 1.0) by 1-year increment] and to a diagnosis 
of Laron syndrome (OR = 4.3; 95% CI: 1.8; 10.6). There 
was no association between the rhIGF-1 dose at the time 
of hypoglycemia and the age at first administration of 
rhIGF-1 therapy.
 The occurrence of other targeted TEAEs is shown in 
 figure 3 . In the treatment-naïve/prepubertal patients 
(n = 107), 92 targeted TEAEs were reported in 41 pa-
tients (38.3%) compared with 63 targeted TEAEs in 33 
pubertal/previously treated patients (n = 78; 42.3%).
 Clinically Significant Laboratory Abnormalities 
 In 29 patients (15.4%), a total of 103 nonserious, clin-
ically significant laboratory abnormalities were report-
ed, of which 15 in 12 patients (6.4%) were considered 
to  be related to treatment. The latter included liver 
and thyroid test abnormalities, decreases in hemoglo-
bin and bilirubin, and out-of-reference ranges for GH–
IGF-1-axis components. A median (95% CI) serum 
IGF-1 concentration of 317 µg/l (281; 386) was reported 
at 12 months (n = 99), related to an increase from base-
line of 237 µg/l [198; 309 (n = 92)]. These levels were not 
defined relative to time of rhIGF-1 injection. The IGF-1 
levels obtained after 1 year did not clearly change with 
increasing treatment duration. In patients who had pre-
viously received growth-promoting therapy, median 
(95% CI) serum IGF-1 concentration increased from 
124 µg/l (76; 161) (n = 51) at baseline to 303 µg/l (221; 
455) (n = 27) at year 1, and 369 µg/l (203; 433) (n = 22) 
at year 2. In contrast, serum IGFBP-3 concentration 
at baseline [median 1,900 µg/l (95% CI: 1,539; 2,200), 
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 Fig. 2. Height velocity at year 2 according to height velocity at year 1 in treatment-naïve/prepubertal children ( a ) and those who had 
previously received growth-promoting therapy or who were pubertal ( b ). 
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n = 120] was unchanged at 1 year [median 1,480 µg/l 
(95% CI: 1,180; 2,000), n = 68; median change 55 µg/l 
(–136; 140), n = 52], with no clear changes with increas-
ing treatment duration.
 Serious Adverse Events 
 A total of 61 SAEs were reported in 31 patients (16.5%). 
Of these, 37 SAEs were considered to be related to rhIGF-1 
therapy ( table 3 ). In the majority of patients, there was no 
change in treatment, or treatment was interrupted or de-
layed. Four patients who were naïve to treatment termi-
nated therapy due to recurrence of injection site reactions 
with redness and swelling, thyroid nodule (biopsy was 
not performed and data to support a malignancy are lack-
ing), angioedema (Quincke’s edema), or splenic infarc-
tion in a patient with a medical history including spleno-
megaly, hypersplenism, and autoimmune lymphoprolif-
erative syndrome. Treatment was terminated due to 
acromegalic facial changes (hypertrophy of the nose; 
 table 3 ) in 1 patient who had previously received growth-
promoting therapy. Premalignant disease (myelodyspla-
sia) leading to death was observed in 1 patient, and after 
review by the sponsor this SAE was considered to be re-
lated to treatment. A further 23 SAEs in 17 patients (9.0%) 
were reported, but were not considered to be related to 
rhIGF-1 therapy by the treating physician. The number 
of SAEs was 35 in the treatment-naïve/prepubertal pa-
tients (15.9% of subpopulation) and 26 in the pubertal/
previously treated patients (17.9%).
 Other Treatment-Related, Nonserious TEAEs 
 There were 29 other treatment-related, nonserious 
TEAEs in 22 patients (11.7%), including endocrine disor-
ders (hypothyroidism, secondary hypothyroidism), hair 
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 Fig. 3. Total and serious targeted TEAEs 
(safety population). Hearing impairment 
was coded as deafness. 
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 Table 3.  Serious TEAEs considered to be treatment related (safety population, n = 188)
AE Events,
n
Patients 
presenting 
at least one
event, n (%)
 Hospitalizeda Change in treatmenta
yes no no
change
dose
changed
delayed/
interrupted
terminated
All 37 24 (12.8)b
Blood and lymphatic system disorders 3 1 (0.5) 1 0 0 0 0 1
Hypersplenismc 1 1 (0.5) 1 0 0 0 0 1
Splenic infarctionc 1 1 (0.5) 1 0 0 0 0 1
Splenomegalyc 1 1 (0.5) 1 0 0 0 0 1
Congenital, familial, and genetic disorders 2 1 (0.5) 1 0 1 0 0 0
Hydrocele 2 1 (0.5) 1 0 1 0 0 0
Eye disorders 1 1 (0.5) 1 0 0 0 1 0
Papilledema 1 1 (0.5) 1 0 0 0 1 0
Gastrointestinal disorders 2 1 (0.5) 1 0 0 0 1 0
Volvulus 1 1 (0.5) 1 0 0 0 1 0
Volvulus of small bowel 1 1 (0.5) 1 0 0 0 1 0
General disorders and administration site conditions 4 3 (1.6) 1 2 0 0 1 2
Hypertrophyd 1 1 (0.5) 0 1 0 0 0 1
Injection site induration 1 1 (0.5) 1 0 0 0 1 0
Injection site pruritus 1 1 (0.5) 1 0 0 0 1 0
Injection site reaction 1 1 (0.5) 0 1 0 0 0 1
Immune system disorders 1 1 (0.5) 1 0 0 0 1 0
Hypersensitivity 1 1 (0.5) 1 0 0 0 1 0
Infections and infestations 1 1 (0.5) 1 0 0 0 1 0
Toxoplasmosis 1 1 (0.5) 1 0 0 0 1 0
Metabolism and nutrition disorders 8 5 (2.7) 4 1 0 2 4 0
Hypoglycemia 8 5 (2.7) 4 1 0 2 4 0
Musculoskeletal and connective tissue disorders 1 1 (0.5) 1 0 1 0 0 0
Arthralgia 1 1 (0.5) 1 0 1 0 0 0
Neoplasms benign, malignant, and unspecified 
(including cysts and polyps) 2 2 (1.1) 1 1 0 0 0 2
Thyroid neoplasme 1 1 (0.5) 0 1 0 0 0 1
Myelodysplastic syndromef 1 1 (0.5) 1 0 0 0 0 1
Nervous system disorders 3 3 (1.6) 2 1 0 0 3 1
Headacheg 1 1 (0.5) 0 1 0 0 1 0
Hypoglycemic unconsciousnessh 2 2 (1.1) 2 0 0 0 1 1
Paresthesia 1 1 (0.5) 1 0 0 0 1 0
Reproductive system and breast disorders 2 2 (1.1) 1 1 1 0 1 0
Ovarian enlargementg 1 1 (0.5) 0 1 0 0 1 0
Testicular torsion 1 1 (0.5) 1 0 1 0 0 0
Respiratory, thoracic, and mediastinal disorders 5 4 (2.1) 4 0 3 0 1 0
Adenoidal hypertrophy 3 3 (1.6) 3 0 3 0 0 0
Tonsillar hypertrophy 2 2 (1.1) 2 0 1 0 1 0
Skin and subcutaneous tissue disorders 2 2 (1.1) 1 1 0 0 1 1
Angiedema 1 1 (0.5) 0 1 0 0 0 1
Dermatitis allergic 1 1 (0.5) 1 0 0 0 1 0
 a Number of patients . b Includes 1 case of myelodysplastic syndrome reported as unrelated to treatment by physician but considered related 
to treatment by sponsor (see footnote f). c Splenomegaly and hypersplenism were preexisting and part of the patient’s autoimmune lympho-
proliferative syndrome; type 1 diabetes mellitus complicated by retinopathy and hypothyroidism was also preexisting. d Soft tissue (nose) hy-
pertrophy. e Negative for tumor markers; underwent sonography every 3 months with no progress; biopsy/pathological evaluation not  considered 
necessary. f Premalignant disease (myelodysplasia) leading to death, reported as unrelated to treatment by physician but considered related to 
treatment by sponsor. g Considered serious, as associated with significant disability/incapacity. h One patient with hypoglycemic unconscious-
ness, reported as unrelated to treatment by physician but considered related to treatment by sponsor.
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disorders (alopecia, dandruff, hair texture abnormal, hair 
growth abnormal), and clinical signs (abdominal pain, as-
thenia, hepatosplenomegaly, central obesity, bone pain, 
melanocytic nevus, dysplastic nevus, dyspnea and snor-
ing, allergic pruritus, weight increase, dizziness, adenoi-
dal hypertrophy, arthralgia).
 Completion or Termination of rhIGF-1 Therapy 
 Ten of 195 patients (5.1%) completed the study be-
cause they were reported to have reached their adult or 
near-adult height. SPIGFD was listed as the primary di-
agnosis in 8 patients, of which 4 had Laron syndrome 
(GHR gene defect). Primary diagnoses in the 2 remaining 
patients were GH gene defects associated with the devel-
opment of anti-rhGH antibodies, and PIGFD with an IGF 
gene defect. These patients achieved a mean adult height 
SDS ± SD of –3.4 ± 2.0 (range: 0.46 to –6.5 SDS) with a 
mean ± SD treatment duration of 1,078.3 ± 327.2 days. 
rhIGF-1 therapy was ended at a median age (range) of 
17.3 years (16.2–21.1). Of the 4 patients who achieved 
adult height SDS of less than –3.4, all were pubertal before 
starting rhIGF-1 treatment and 3 had a severe phenotype 
at baseline with a height SDS of less than –5.0.
 Treatment was terminated in 57 of 195 patients 
(29.2%); termination was due to an AE in 6 patients (3.1%; 
for SAEs, see above and  table  3 ), noncompliance with 
therapy in 3 patients (1.5%), lack of effectiveness in 16 
patients (8.2%), and patient/parent or physician choice 
in 18 patients (9.2%). A further 14 patients (7.2%) ter-
minated treatment for other reasons.
 Discussion 
 This is the first published report of the safety and ef-
fectiveness of rhIGF-1 treatment of short stature in clin-
ical practice across 10 European countries, representing 
60% of the treated European population  [14] . The first-
year height velocity was 7.3 cm/year in treatment-naïve, 
prepubertal children and 7.4 cm/year in those treated 
with an rhIGF-1 dose of >100 µg/kg BID, approaching 
the maximum recommended dose of 120 µg/kg BID in 
the Increlex ® product label. Among the treatment-naïve/
prepubertal patients, those with Laron syndrome were 
younger and shorter at baseline, and had a better gain in 
height SDS after 1 year of treatment. This is in line with 
our observation that younger age and lower height SDS 
at baseline predicted a better response in treatment- 
naïve/prepubertal patients. Furthermore, it was evident 
from the baseline data that not all of the treatment-naïve/
prepubertal patients reported to have SPIGFD fulfilled 
the diagnostic criteria in the EU: height less than –3 SDS, 
IGF-1 <2.5th percentile (approx. less than –2 SDS), and 
normal GH secretion.
 Hypoglycemia was the most frequently reported AE in 
the EU IGFD Registry. Univariate analysis showed that a 
diagnosis of Laron syndrome or young age at baseline 
tended to increase the risk of hypoglycemia, which sup-
ports the existence of a predestined risk of hypoglycemia 
in SPIGFD  [10] . Eight hypoglycemic events in 5 patients 
were reported as SAEs, which strongly emphasizes that 
the recommendations in the Increlex ® product label to 
administer treatment shortly before or after a meal or 
snack should be strictly followed. There was an accumu-
lation of SAEs in a few patients with complicated comor-
bidity in addition to their short stature, and this is clearly 
a group in which caution should be taken and the indica-
tion for treatment reconsidered.
 Patient diagnoses were reported by the treating physi-
cians. Reporting in similar registries of rhGH therapy has 
revealed that when applying strict diagnostic criteria 
many patients will have their reported diagnosis changed 
 [15] . We were unable to confirm a primary diagnosis of 
SPIGFD in patients enrolled in the EU IGFD Registry. 
Central laboratory analysis was not used in the EU IGFD 
Registry and many IGF-1 assays in clinical practice do not 
define the 2.5th percentile (or –2 SDS). In previously 
treated/pubertal patients, baseline IGF-1 could be con-
founded by ongoing rhGH or rhIGF-1 treatment. How-
ever, this was not the case in treatment-naïve/prepubertal 
patients, in whom the high median IGF-1 at baseline sug-
gested that less than the reported 90% of patients fulfilled 
the IGF-1 requirement. In the treatment-naïve/prepu-
bertal patients, we evaluated the compliance with the def-
inition of SPIGFD with respect to height SDS of less than 
–3; in those reported to have SPIGFD, only 7 patients had 
a baseline SDS greater than –3 SDS according to the in-
vestigator, but 48 patients had a calculated baseline SDS 
greater than –3 SDS. In the previously treated/pubertal 
patients with SPIGFD, 9 had a reported baseline height 
SDS greater than –3 SDS while 23 had a calculated base-
line height SDS greater than –3 SDS. In some of these pa-
tients, previous rhIGF-1 treatment may have improved 
height before enrolment in the EU IGFD registry. Fewer 
than 25% of the treatment-naïve/prepubertal patients 
had a stimulated GH maximum below 10 ng/ml (25th 
percentile: 11.0 ng/ml). A high stimulated GH maximum 
and/or elevated spontaneous baseline GH are character-
istics of GH insensitivity  [16] while the diagnostic criteria 
for SPIGFD is ‘normal or elevated GH secretion’. The lack 
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of consensus on how to define the cutoff between GHD 
and normal makes it hard to establish which GH status 
should define SPIGFD.
 Given that registries rely on the collection of preexist-
ing clinical data, we were unable to confirm the diagno-
sis of SPIGFD and thereby look for height responses in 
patients other than those in the Laron subgroup. There-
fore, we used multiple regression analysis to identify 
height response markers as well as assess the effective-
ness of rhIGF-1 therapy in children who were naïve to 
treatment and prepubertal at baseline. We identified 
young age and low height SDS as positive predictors of 
first-year change in height SDS. Our finding suggests 
that treatment should be started early in life and should 
be restricted to children who fulfill the diagnostic crite-
ria of SPIGFD. Optimal height response to rhGH treat-
ment in children with approved indications is also 
achieved in those who are young and short at the start 
of treatment  [15, 16] . However, a mean age of 8.5 years 
(as per the treatment-naïve/prepubertal children at start 
of rhIGF-1 treatment) is a common starting age for 
rhGH therapy (reviewed in  [16] ). Another positive pre-
dictor of first-year gain in height SDS was female sex. 
We are unsure about how this result should be inter-
preted. The rhIGF-1 dose was not identified as a predic-
tor of first-year height velocity or gain in height SDS, 
and thus does not confirm the importance of dose in 
previous trials of rhIGF-1 therapy in less severe primary 
IGF-1 deficiency patients  [12] .
 The mean first-year height velocity of 7.4 cm in the 
treatment-naïve/prepubertal patients treated with an 
rhIGF-1 dose >100 µg/kg BID was comparable with re-
sponses reported in rhIGF-1 trials in SPIGFD  [10, 11] and 
in the recent rhIGF-1 trial in less severe IGF-1 deficien-
cy defined as height and IGF-1 SDS less than –2 and GH 
maximum >7 ng/ml  [12] . These height responses are 
slightly less than the response to rhGH in idiopathic GHD 
but significantly less than those in severe GHD  [15, 17] . 
IGF-1-independent growth-promoting effects of GH, as 
well as the IGF-1-supporting actions of GH-dependent 
IGFBP-3 and ALS, are thought to be important for this 
difference. In a study of long-term follow-up to adult or 
near-adult height of patients with SPIGFD who received 
rhIGF-1 treatment, an increase in BMI and body fat mea-
sured by dual-energy X-ray absorptiometry was reported 
 [18] . We found that BMI increased, approaching 0 SDS 
during the first year of treatment. The risk of future obe-
sity resulting from slightly faster catch-up of weight ver-
sus height cannot be ruled out. However, accumulation 
of fat appears to be a late event, as supported by the early 
loss of adiposity on dual-energy X-ray absorptiometry 
when re-starting rhIGF-1 therapy reported in 2 patients 
with Laron syndrome  [19] .
 We did not observe any new safety signals in the EU 
IGFD Registry compared with those previously reported 
in children treated with rhIGF-1. The targeted TEAEs 
reported in the EU IGFD Registry were less frequent 
compared with previous rhIGF-1 treatment trials of 
SPIGFD  [10, 11] but of a similar frequency to those in 
less severe primary IGF-1 deficiency  [12] . Hypoglyce-
mia, suspected or verified by determination of blood 
 glucose, was the most common targeted TEAE, confirm-
ing previous observations. Younger age at the time of 
first rhIGF-1 dose and a diagnosis of Laron syndrome 
increased the risk of hypoglycemia, whereas rhIGF-1 
dose and time from start of rhIGF-1 treatment did not 
affect the risk. This is the first published risk assessment 
of hypoglycemia that has been undertaken in clinical 
practice for rhIGF-1-treated children with short stature. 
In this assessment, we cannot exclude the possibility that 
failure to identify the effect of dose is influenced by fail-
ure to complete dose escalation to the recommended ef-
fective dose of 120 µg/kg/day BID in patients with an 
expected risk of hypoglycemia. However, the specific risk 
of hypoglycemia associated with dose was not found in 
the trial by Midyett et al.  [12] .
 The EU IGFD Registry database has included patients 
since December 2008. Only 10 patients have reached 
adult or near-adult height with a mean of less than –3.4 
SDS. In patients with SPIGFD, similar adult or near-adult 
height was reported by Backeljauw et al.  [18] . In the EU 
IGFD Registry, of the 4 patients with a final or near adult 
height less than –3.4 SDS, 3 had an adult height SDS less 
than –5.0. Two patients with genetically verified defects 
in the GH receptor  [19] and with an adult height expec-
tancy of 120–130 cm, reached adult heights of 156.5 and 
160.6 cm, respectively, which are extremely valuable re-
sults. The finding that almost one third of the patients 
terminated treatment before reaching adult height may 
seem worrying, even though this was due to AEs in only 
a few patients. The number of patients reporting poor 
compliance as a reason for stopping treatment was low 
considering the twice-daily injection schedule, and poor 
compliance may have contributed to the poor response 
observed in some patients.
 In conclusion, data from patients in the real-world 
clinical setting of the EU IGFD Registry are similar to 
those from previous clinical trials, and therefore confirm 
the efficacy and safety profiles of rhIGF-1 therapy, previ-
ously reported in those trials.
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